Brought to you by 
Instead of IPO, Aptalis takes $2.9bn acquisition offer from Forest Laboratories
03 Jun 2021
Executive Summary
Less than two weeks after filing an S-1 to go public, private spec pharma Aptalis Holdings Inc. scrapped those plans and instead agreed to be acquired by Forest Laboratories Inc. for $2.9bn in cash.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Instead of IPO, Aptalis takes $2.9bn acquisition offer from Forest Laboratories
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice